TABLE 2.
Characteristics of Female Patients Who Received Their First HPV4 Dose Between June 2006 and June 2008 (N = 3297)
| Characteristic | Value |
|---|---|
| Age, mean (SD), y | 15.3 (2.5) |
| Age group, n (%) | |
| 9–10 y | 140 (4.2) |
| 11–12 y | 515 (15.6) |
| 13–18 y | 2458 (74.6) |
| 19–26 y | 184 (5.6) |
| Race, n (%) | |
| Black | 2218 (67.3) |
| White | 942 (28.6) |
| Othera | 137 (4.2) |
| Insurance used for HPV4 dose 1, n (%) | |
| Private | 1007 (31.0) |
| Public | 2144 (66.1) |
| None | 94 (2.9) |
| Pregnancy during 12-mo completion period (yes), n (%) | 66 (2.0) |
| DMPA at HPV4 dose 1 (yes), n (%) | 346 (10.5) |
| DMPA during 7-mo completion period (yes), n (%) | 647 (19.6) |
| DMPA during 12-mo completion period (yes), n (%) | 728 (22.1) |
| Clinic location of HPV4 dose 1, n (%) | |
| Pediatrics | 858 (26.0) |
| Adolescent base | 2250 (68.2) |
| Adolescent satellite clinics | 148 (4.5) |
| Specialty clinics | 41 (1.2) |
| Time period of vaccine series initiation, n (%) | |
| November 2006—March 2007 | 478 (14.5) |
| April 2007—August 2007 | 1096 (33.2) |
| September 2007—January 2008 | 941 (28.5) |
| February 2008—June 2008 | 782 (23.7) |
The denominator for percentages is the number of female patients who received at least 1 HPV4 dose. DMPA indicates depot medroxyprogesterone acetate.
a
Includes Asian, mixed race, American Indian, and other.